- Pertuzumab:
- Is approved for use preoperatively in advanced disease and in the metastatic setting
- Trastuzumab:
- Is approved for use in neoadjuvant, adjuvant, and metastatic settings
- Ado-trastuzumab-emtansine and lapatinib:
- Are approved for use in the metastatic setting:
- Among patients who have progressed on previous lines of systemic chemotherapy, including trastuzumab
- Are approved for use in the metastatic setting:
- Lapatinib:
- Is an oral small molecule receptor tyrosine kinase inhibitor of both:
- HER2 and EGFR
- Is an oral small molecule receptor tyrosine kinase inhibitor of both:
- Trastuzumab and pertuzumab:
- Are humanized monoclonal antibodies:
- That target the extracellular HER2 domain
- However, pertuzumab:
- Binds to a different HER2 epitope than trastuzumab:
- Resulting in more HER2 blockade when they are given together
- Binds to a different HER2 epitope than trastuzumab:
- Are humanized monoclonal antibodies:
- Ado-trastuzumab-emtansine:
- Is a HER2-antibody drug conjugate:
- That incorporates trastuzumab with emtansine:
- A microtubule inhibitor DM1:
- The conjugate:
- Which is linked via a stable thioether linker:
- Allows for selective delivery into HER2 overexpressing cells:
- Resulting in cell cycle arrest and apoptosis
- Allows for selective delivery into HER2 overexpressing cells:
- Which is linked via a stable thioether linker:
- That incorporates trastuzumab with emtansine:
- Is a HER2-antibody drug conjugate:
REFERENCES
- Lin JJ, Cardarella S, Lydon CA, et al. Five-year survival in EGFR-mutant metastatic lung adenocarcinoma treated with EGFR-TKIs. J Thorac Oncol. 2016;11(4):556-565.
- Weickhardt AJ, Price TJ, Chong G, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol. 2012;30(13):1505-1512.
- Jiang H, Rugo HS. Human epidermal growth factor receptor 2 positive (HER2+) metastatic breast cancer: how the latest results are improving therapeutic options. Ther Adv Med Oncol. 2015;7(6):321-339.
#Arrangoiz #BreastCancer #CancerSurgeon #SurgicalOncology #BreastSurgeon